BACKGROUND: Capecitabine, an oral 5-fluorouracil (5-FU) prodrug, is widely used in the treatment of breast, colorectal, and gastric cancers. To guide the selection of patients with potentially the greatest benefit of experiencing antitumor efficacy, or, alternatively, of developing toxicities, identifying genomic predictors of capecitabine sensitivity could permit its more informed use. METHODS: The objective of this study was to perform capecitabine sensitivity genome-wide association studies (GWAS) using 503 well genotyped human cell lines from individuals representing multiple different world populations. A meta-analysis that included all ethnic populations then enabled the identification of novel germline determinants (single nucleotide polymorphisms [SNPs]) of capecitabine susceptibility. RESULTS: First, an intrapopulation GWAS of Caucasian individuals identified reference SNP 4702484 (rs4702484) (within adenylate cyclase 2 [ADCY2]) at a level reaching genome-wide significance (P = 5.2 × 10(-8) ). This SNP is located upstream of the 5 methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR) gene, and it is known that the enzyme for MTRR is involved in the methionine-folate biosynthesis and metabolism pathway, which is the primary target of 5-FU-related compounds, although the authors were unable to identify a direct relation between rs4702484 and MTRR expression in a tested subset of cells. In the meta-analysis, 4 SNPs comprised the top hits, which, again, included rs4702484 and 3 additional SNPs (rs8101143, rs576523, and rs361433) that approached genome-wide significance (P values from 1.9 × 10(-7) to 8.8 × 10(-7) ). The meta-analysis also identified 1 missense variant (rs11722476; serine to asparagine) within switch/sucrose nonfermentable-related, matrix-associated, actin-dependent regulator of chromatin (SMARCAD1), a novel gene for association with capecitabine/5-FU susceptibility. CONCLUSIONS: Toward the goal of individualizing cancer chemotherapy, the current study identified novel SNPs and genes associated with capecitabine sensitivity that are potentially informative and testable in any patient regardless of ethnicity.
BACKGROUND:Capecitabine, an oral 5-fluorouracil (5-FU) prodrug, is widely used in the treatment of breast, colorectal, and gastric cancers. To guide the selection of patients with potentially the greatest benefit of experiencing antitumor efficacy, or, alternatively, of developing toxicities, identifying genomic predictors of capecitabine sensitivity could permit its more informed use. METHODS: The objective of this study was to perform capecitabine sensitivity genome-wide association studies (GWAS) using 503 well genotyped human cell lines from individuals representing multiple different world populations. A meta-analysis that included all ethnic populations then enabled the identification of novel germline determinants (single nucleotide polymorphisms [SNPs]) of capecitabine susceptibility. RESULTS: First, an intrapopulation GWAS of Caucasian individuals identified reference SNP 4702484 (rs4702484) (within adenylate cyclase 2 [ADCY2]) at a level reaching genome-wide significance (P = 5.2 × 10(-8) ). This SNP is located upstream of the 5 methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR) gene, and it is known that the enzyme for MTRR is involved in the methionine-folate biosynthesis and metabolism pathway, which is the primary target of 5-FU-related compounds, although the authors were unable to identify a direct relation between rs4702484 and MTRR expression in a tested subset of cells. In the meta-analysis, 4 SNPs comprised the top hits, which, again, included rs4702484 and 3 additional SNPs (rs8101143, rs576523, and rs361433) that approached genome-wide significance (P values from 1.9 × 10(-7) to 8.8 × 10(-7) ). The meta-analysis also identified 1 missense variant (rs11722476; serine to asparagine) within switch/sucrose nonfermentable-related, matrix-associated, actin-dependent regulator of chromatin (SMARCAD1), a novel gene for association with capecitabine/5-FU susceptibility. CONCLUSIONS: Toward the goal of individualizing cancer chemotherapy, the current study identified novel SNPs and genes associated with capecitabine sensitivity that are potentially informative and testable in any patient regardless of ethnicity.
Authors: R Stephanie Huang; Shiwei Duan; Emily O Kistner; Wasim K Bleibel; Shannon M Delaney; Donna L Fackenthal; Soma Das; M Eileen Dolan Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: Heather E Wheeler; Eric R Gamazon; Claudia Wing; Uchenna O Njiaju; Chidiamara Njoku; Robert Michael Baldwin; Kouros Owzar; Chen Jiang; Dorothy Watson; Ivo Shterev; Michiaki Kubo; Hitoshi Zembutsu; Eric P Winer; Clifford A Hudis; Lawrence N Shulman; Yusuke Nakamura; Mark J Ratain; Deanna L Kroetz; Nancy J Cox; Mary Eileen Dolan Journal: Clin Cancer Res Date: 2012-11-30 Impact factor: 12.531
Authors: Heather E Wheeler; Anna González-Neira; Guillermo Pita; Julio-Cesar de la Torre-Montero; Rosario Alonso; Luis A Lopez-Fernandez; Emilio Alba; Miguel Martín; M Eileen Dolan Journal: Pharmacogenet Genomics Date: 2014-05 Impact factor: 2.089
Authors: Kathleen N Moore; David Tritchler; Kenneth M Kaufman; Heather Lankes; Michael C J Quinn; Linda Van Le; Andrew Berchuck; Floor J Backes; Krishnansu S Tewari; Roger B Lee; Joshua P Kesterson; Robert M Wenham; Deborah K Armstrong; Thomas C Krivak; Michael A Bookman; Michael J Birrer Journal: Gynecol Oncol Date: 2017-09-19 Impact factor: 5.482
Authors: Han Han; Guangzhen Jiang; Rashmi Kumari; Martin R Silic; Jake L Owens; Chang-Deng Hu; Suresh K Mittal; GuangJun Zhang Journal: Genes Chromosomes Cancer Date: 2021-08-07 Impact factor: 4.263
Authors: Amy L Stark; Ronald J Hause; Lidija K Gorsic; Nirav N Antao; Shan S Wong; Sophie H Chung; Daniel F Gill; Hae K Im; Jamie L Myers; Kevin P White; Richard Baker Jones; M Eileen Dolan Journal: PLoS Genet Date: 2014-04-03 Impact factor: 5.917